← Back to Clinical Trials
Recruiting NCT05206305

Sensory-Evoked Cortical Gamma Oscillation

Trial Parameters

Condition Alzheimer Disease
Sponsor University of Tennessee Medical Center
Study Type INTERVENTIONAL
Phase N/A
Enrollment 20
Sex ALL
Min Age 60 Years
Max Age N/A
Start Date 2022-07-01
Completion 2025-12-31
Interventions
GammaSense Stimulation device

Brief Summary

The purpose of the study is to investigate the efficacy of cortical gamma oscillation on visual sensory processing and cognitive function in Alzheimer's Disease (AD) patients by combining a therapeutic sensory stimulation device capable of evoking 40-Hz gamma oscillation via non-invasive visual and auditory stimulation with pre-established markers of cortical network activity, i.e., electroencephalography (EEG) and event-related potentials (ERP), to evaluate the applicability of the 40-Hz multimodel sensory stimulation as a novel therapeutic approach for treatment of AD patients.

Eligibility Criteria

Inclusion Criteria: * Individuals ages 60 and older with established diagnosis of Alzheimer's Disease as defined by the current consensus criteria for AD (Albert et al, 2011, Jack et al, 2011; McKhann et al, 2011) * Fluent and literate in English language * Able to consent for themselves based upon the MacArthur Competence Assessment Tool for Clinical Research * Patients with a pre-existing positive A(beta)-PET and/or CSF tau/A(beta) markers or willingness to undergo a Lumbar Puncture (LP) with these results Exclusion Criteria: * Not fluent and literate in English * Severe dementia * Other medical conditions/neurodegenerative disease that could significantly impair cognitive abilities * Cardiac pacemakers or any other implants that may not be compatible with MRI * Cognitively impaired to the point the patient is unable to consent for themselves * Claustrophobic to the point that medication is required

Related Trials